abrdn Life Sciences Investors (NYSE:HQL) Sets New 1-Year High – Time to Buy?

abrdn Life Sciences Investors (NYSE:HQL)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $21.42 and last traded at $21.3610, with a volume of 23881 shares trading hands. The stock had previously closed at $21.24.

abrdn Life Sciences Investors Price Performance

The company’s 50-day moving average price is $19.19 and its two-hundred day moving average price is $17.84.

abrdn Life Sciences Investors Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, August 24th will be paid a $0.62 dividend. The ex-dividend date is Monday, August 24th. This represents a $2.48 dividend on an annualized basis and a yield of 11.7%.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several hedge funds have recently bought and sold shares of the stock. Geneos Wealth Management Inc. boosted its holdings in shares of abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after acquiring an additional 1,529 shares during the period. Global Retirement Partners LLC increased its stake in shares of abrdn Life Sciences Investors by 187.8% during the fourth quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after purchasing an additional 4,593 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in shares of abrdn Life Sciences Investors during the fourth quarter worth approximately $177,000. Evolve Private Wealth LLC acquired a new stake in abrdn Life Sciences Investors during the 4th quarter worth approximately $199,000. Finally, Independent Financial Group LLC acquired a new stake in abrdn Life Sciences Investors during the 1st quarter worth approximately $211,000. 32.21% of the stock is currently owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.